Refractory Small Lymphocytic Lymphoma Clinical Trials

41 clinical trials for Refractory Small Lymphocytic Lymphoma across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia — RECRUITING · PHASE2
• Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — RECRUITING · PHASE2
• CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies — RECRUITING · PHASE1
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies — RECRUITING · PHASE2
• Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial — RECRUITING · PHASE2
• Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma — RECRUITING · PHASE2
• B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies — RECRUITING · PHASE1
• Q702 for the Treatment of Patients With Hematologic Malignancies — RECRUITING · PHASE1
• Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies — TERMINATED · PHASE1
• Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas — COMPLETED · PHASE2
• A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas — ACTIVE_NOT_RECRUITING · PHASE1
• Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery — ACTIVE_NOT_RECRUITING · PHASE1
• Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study — TERMINATED · PHASE2
• Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma — COMPLETED · PHASE1
• Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation — WITHDRAWN · PHASE1
• Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma — TERMINATED · PHASE2
• CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL — WITHDRAWN · PHASE1
• Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation — COMPLETED · PHASE2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial — TERMINATED · PHASE1
• Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor — WITHDRAWN · PHASE1
• Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial — COMPLETED · PHASE1
• Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — TERMINATED · PHASE2
• Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — COMPLETED · PHASE1
• Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia — COMPLETED · PHASE1
• Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL — WITHDRAWN · PHASE1
• Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma — COMPLETED · PHASE1
• Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL — COMPLETED · PHASE2
• CD19-Specific T Cells Post AlloSCT — TERMINATED · PHASE1
• NK Cells in Cord Blood Transplantation — OTHER · PHASE1
• Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer — COMPLETED · PHASE1
• Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma — COMPLETED · PHASE1
• Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer — COMPLETED · PHASE2
• Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia — TERMINATED · PHASE1
• Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia — COMPLETED · PHASE2

Refine this search